Clinical trials: COVID-19 Prevention
COVID-19
Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine
This is a randomized, placebo-controlled, two center, Phase I trial in healthy adult volunteer participants consisting of two phases, an unblinded dose escalation and a double blind treatment phase to investigate the safety…
- Trial name
- COVID-19-101 (NCT04497298)
- Testing
- Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose, Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose, One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose
- Where
- 2 sites in Belgium, France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19
Study of VYD2311 for the Prevention of COVID-19
The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19.
- Trial name
- DECLARATION (NCT07298434)
- Testing
- VYD2311-SD, VYD2311-MD
- Where
- 20 sites in United States
- Volunteers
- 1,770 people, healthy volunteers welcome
- Sponsor
- Invivyd, Inc.
COVID-19
Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study
This is a dose exploration study to evaluate the safety and pharmacokinetics (PK) of AZD3152 in healthy adult male and female participants, across different dose levels and routes of administration (ie, Intramuscular [IM]…
- Trial name
- NCT05872958
- Testing
- AZD3152
- Where
- 4 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19
Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults
This study is an open-label phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine(CoronaVac)manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04962308
- Testing
- SARS-CoV-2 Inactivated Vaccine, The SARS-CoV-2 Inactivated Vaccine
- Where
- China
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Coronavirus Disease-2019 (COVID-19) Prevention
A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive
The primary purpose of this study is to assess the safety, reactogenicity, and humoral immune response of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule or as a 2-dose schedule (56-day interval) in adolescents.
- Trial name
- HORIZON 2 (NCT05007080)
- Testing
- Ad26.COV2.S
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Covid19
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
This is a Phase 1 clinical trial to assess the safety and immunogenicity of AdCLD-CoV19-1 in healthy adults.
- Trial name
- NCT05047692
- Testing
- AdCLD-CoV19-1
- Where
- 3 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
Covid19, Prophylaxis
Mesenchymal Stem Cells for the Treatment of COVID-19
This double blind, placebo controlled, multi-arm, multi-site study investigates the safety and efficacy of stem cell therapy for the treatment of patients admitted to hospital suffering complications from COVID-19 and the…
- Trial name
- NCT04573270
- Testing
- PrimePro
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Thomas Advanced Medical LLC
COVID-19 Respiratory Infection
Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19
The main purpose of this study is to evaluate the effectiveness of the prophylactic use of Ingaron (INN: recombinant interferon gamma human, lyophilisate for solution for intranasal administration 100,000 IU) in the regimen of 3…
- Trial name
- NCT05386446
- Testing
- Interferon gamma human recombinant (IFN-G)
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- SPP Pharmaclon Ltd.
Covid19 Vaccine
PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.
The Vaccine Product, PTX-COVID19-B mRNA Humoral Vaccine, is intended for prevention of COVID-19 in a general population. This study is designed to evaluate the safety, tolerability, and immunogenicity of PTX-COVID19-B compared to…
- Trial name
- NCT05175742
- Testing
- PTX-COVID19-B, Pfizer-BioNTech COVID-19 vaccine
- Where
- 11 sites in Canada, South Africa
- Volunteers
- 565 people, healthy volunteers welcome
- Sponsor
- Providence Therapeutics Holdings Inc.